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Introduction {#sec1}
============

Ras proteins are members of a superfamily of small GTPases that transmit signals from cell-surface receptor tyrosine kinases (RTKs) to activate multiple downstream cell signaling pathways ([@bib42]). Ras proteins thereby occupy a key position in the signaling network controlling numerous cellular processes, including proliferation, differentiation, apoptosis, senescence, and metabolism ([@bib21]). Hyper-activation of Ras is highly oncogenic, and approximately one-third of human tumors present with *ras* mutation, a context in which Ras has been extensively studied ([@bib45]).

Ras proteins are molecular switches that cycle between an inactive GDP-bound state and an active GTP-bound state, the balance of which is determined by the competing activities of guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) ([@bib21; @bib45]). In its active, GTP-bound conformation, Ras has high affinity for numerous downstream effectors of RTK signal transduction pathways, including Raf, thereby activating the extracellular signal-regulated kinase (Erk)/mitogen-activated protein kinase (Mapk)-signaling cascade and the p110 catalytic subunit of the class 1 phosphatidylinositol 3-kinase (PI3K), leading to activation of the PI3K-Akt-signaling cascade ([@bib21; @bib45]).

Deletion of *RAS2*, one of two Ras paralogs in the budding yeast, has long been known to extend chronological lifespan ([@bib17]). Recent experiments in mice indicate that this pro-longevity function of Ras inhibition may be conserved. Mice deficient in *RasGrf1*, which encodes a tissue-specific guanine exchange factor for Ras ([@bib19]), have been reported to live longer and maintain a better level of motor coordination in old age than their wild-type littermates ([@bib8]). However, involvement of Ras in determining metazoan lifespan awaits direct confirmation, as RasGrf1 has affinity for several other ligands, including Rac, Rho, microtubules, PI\[4,5\]P2, and fasfatidic acid ([@bib32]).

In mammals, Ras is a well-established signaling intermediary of the insulin/IGF-1-signaling (IIS) pathway ([@bib50]), which plays an evolutionarily conserved role in the modulation of animal lifespan ([@bib20; @bib25; @bib30]). Central to the capacity of reduced IIS to extend lifespan is the regulation of the Forkhead box O (Foxo) transcription factor via the PI3K-Akt-Foxo branch ([@bib20; @bib37; @bib44]), yet there are no reported pharmacological inhibitors that target this signaling pathway to increase lifespan in any species. A role for Ras downstream of IIS in the control of aging has remained largely unexplored despite its potential to offer novel molecular targets for anti-aging therapeutics.

In this study, we examine the role of Ras and its downstream signaling effectors, Erk, and the E-twenty six (ETS) transcription factors (TFs) during aging in *Drosophila*. We report that attenuation of Ras-Erk-ETS signaling is implicated in the effects of reduced IIS on aging and show that direct inhibition of Ras-Erk-ETS signaling is sufficient to extend lifespan. Importantly, we identify trametinib, a potent small-molecule inhibitor of Ras-Erk-ETS signaling, as an anti-aging intervention. These findings thereby define the inhibition of Ras-Erk-ETS signaling as an important pro-longevity mechanism that can be pharmacologically manipulated to extend animal lifespan.

Results {#sec2}
=======

Ras Functions Downstream of IIS in Lifespan Regulation {#sec2.1}
------------------------------------------------------

The insulin receptor substrates (IRS) couple insulin receptor stimulation to the activation of downstream signaling pathways. By binding to Grb2/Drk protein---which in turn acts as an adaptor for the Ras GEF, SOS---IRS proteins recruit activated Ras to the activated insulin receptor.

In order to analyze the contribution of Ras-Erk signaling to IIS-dependent lifespan extension in *Drosophila*, we mutated the proposed binding site for Grb2/Drk in the single *Drosophila* IRS protein, Chico ([Figure 1](#fig1){ref-type="fig"}A). We first confirmed that this mutation disrupts the interaction between the *Drosophila* Chico and Grb2/Drk proteins upon insulin stimulation in vivo using the bimolecular fluorescence complementation (BiFC) assay in cultured S2 cells. Wild-type (Chico-WT) and Grb2/Drk-binding mutant forms of Chico (Chico-Grb2/Drk) were tagged at their C termini with the N-terminal fragment of YFP (\[N\]YFP), and *Drosophila* Drk was tagged with the C-terminal fragment of YFP (\[C\]YFP-Drk). Each of the YFP fragments is non-fluorescent, but an interaction between the proteins of interest brings them in close proximity, allowing YFP to reform and emit a fluorescent signal. In the absence of insulin, co-expression of Chico-WT-\[N\]YFP or Chico-Grb2/Drk-\[N\]YFP with \[C\]YFP-Drk did not result in significant YFP fluorescence ([Figure 1](#fig1){ref-type="fig"}B). Insulin stimulation of cells co-expressing Chico-WT-\[N\]YFP with \[C\]YFP-Drk produced strong YFP fluorescence ([Figure 1](#fig1){ref-type="fig"}B, effect of insulin, p = 0.003), but not in cells co-expressing Chico-Grb2/Drk-\[N\]YFP with \[C\]YFP-Drk ([Figure 1](#fig1){ref-type="fig"}B, effect of insulin, p = 0.67). Thus, mutation of the Grb2/Drk-binding site in *Drosophila* Chico prevented its direct interaction with Drk in vivo.

To examine the role of the Grb2/Drk-binding site in fly physiology, we generated flies carrying this mutation as a genomic rescue construct alongside genomic rescue constructs containing the wild-type *chico* sequence as well as a second construct with mutations to disrupt binding of Chico to the p60 subunit of PI3K ([Figure 1](#fig1){ref-type="fig"}A). All constructs included the *cis*-regulatory sequences to allow *chico* expression in its normal spatial and temporal pattern and were inserted into the same genomic location, producing similar levels of *chico* mRNA expression ([Figure S1](#figs1){ref-type="fig"}A).We were therefore able to assess the ability of wild-type or mutant forms of Chico to complement the phenotypes of *chico* loss-of-function mutants under equivalent physiological conditions.

To validate our experimental strategy, we examined the previously characterized role of the different domains of Chico in cell proliferation and growth ([@bib35]). We confirmed that the wild-type *chico* genomic rescue construct fully restored several phenotypic defects associated with *chico* null mutation, including developmental delay, reduced growth ([Figures 1](#fig1){ref-type="fig"}C and 1D), female sterility, and increased glycogen and lipid storage ([Figures S1](#figs1){ref-type="fig"}B--S1D). The Grb2/Drk-binding site mutant also fully rescued these phenotypes to the same extent as the wild-type rescue construct, confirming that the presence of a functional Grb2/Drk-binding site is not required for these functions of Chico ([Figures 1](#fig1){ref-type="fig"}C, 1D, and [S1](#figs1){ref-type="fig"}B--S1D). The PI3K-binding mutant behaved similarly to complete loss of *chico* function ([Figures 1](#fig1){ref-type="fig"}C, 1D, and [S1](#figs1){ref-type="fig"}B--S1D), confirming that Chico requires PI3K docking sites for its wild-type function in growth and metabolism ([@bib35]), thereby substantiating our genetic approach.

We then examined the ability of our genomic rescue constructs to rescue the lifespan extension associated with *chico* mutation. To circumvent confounding effects of differences in body size, metabolism, and fertility, we performed the lifespan experiments in a *chico* heterozygous background, where these phenotypes are not obvious ([@bib35]). *chico* heterozygotes were long-lived compared to wild-type controls ([Figure 1](#fig1){ref-type="fig"}E, median lifespan +12%, p = 0.0006). As expected, the wild-type *chico* construct was able to fully restore the lifespan of *chico/+* to that of wild-type flies ([Figure 1](#fig1){ref-type="fig"}E, p = 0.58). In contrast, the PI3K-binding mutant failed to rescue *chico* lifespan extension ([Figure 1](#fig1){ref-type="fig"}E, p = 1.32 × 10^−9^). Interestingly, the Grb2/Drk-binding mutant also failed to rescue the *chico* lifespan extension ([Figure 1](#fig1){ref-type="fig"}E, p = 8.36 × 10^−10^), and both the PI3K-binding and Grb2/Drk-binding mutants showed an increase in median lifespan of 15% compared to the wild-type control. To compare the extent of lifespan extension between the two mutants, we used Cox proportional hazards (CPH) analysis with relevant a priori contrasts: the lifespan extension observed in the Grb2/Drk-binding mutant was not significantly different from that in the PI3K-binding mutant (p = 0.98, [Table S1](#mmc2){ref-type="supplementary-material"}A). Thus, inhibition of signaling from Chico to Ras was sufficient to extend lifespan and to the same degree as inhibition of signaling from Chico to PI3K.

Having established that the presence of a functional Grb2/Drk-binding site in Chico is required for its wild-type function in lifespan, we tested whether ectopic activation of Ras can block the beneficial effects of *chico* mutation on lifespan. We expressed a constitutively active form of *Drosophila* Ras (*ras*^*\[CA\]*^) under the control of the inducible, ubiquitous *daGS* driver in flies either wild-type or mutant for *chico*. In non-induced flies, mutation of *chico* resulted in a significant increase in lifespan ([Figure 1](#fig1){ref-type="fig"}F, 18% median extension, p = 3.07 × 10^−18^). Ubiquitous expression of *ras*^*\[CA\]*^ in adults using RU486 gave short-lived flies ([Figure 1](#fig1){ref-type="fig"}F, p = 3.97 × 10^−67^), but altering the concentration of dietary yeast improved their survival; thus, their lifespan retained plasticity ([Figure S2](#figs2){ref-type="fig"}A). Nevertheless, mutation of *chico* did not increase their lifespan ([Figure 1](#fig1){ref-type="fig"}F, p = 0.18). CPH confirmed that the presence of the *chico* mutation had a significantly different impact on the survival of flies with induced *ras*^*\[CA\]*^ compared to the non-induced controls (p = 7.10 × 10^−11^, [Table S1](#mmc2){ref-type="supplementary-material"}B). Hence, activation of Ras is sufficient to prevent any beneficial effects of *chico* mutation on survival.

Direct Inhibition of Ras-Erk Signaling Extends Lifespan {#sec2.2}
-------------------------------------------------------

We next tested whether direct inhibition of Ras itself is sufficient to extend lifespan by expressing a dominant-negative form of human Ras (*ras*^*\[DN\]*^). Adult-onset, ubiquitous expression of *ras*^*\[DN\]*^ resulted in a modest but significant lifespan extension ([Figure 2](#fig2){ref-type="fig"}A, median survival +8%, p = 1.26 × 10^−7^). In addition, we examined the effects on lifespan of RNAi-mediated knockdown of expression of the *Drosophila ras85D* gene (*ras85D*^*\[RNAi\]*^). Adult-onset, ubiquitous RNAi against *ras85D* also resulted in a significant increase in lifespan ([Figure 2](#fig2){ref-type="fig"}B, median survival +4%, p = 0.002), confirming that reducing Ras activity is sufficient to extend lifespan.

The canonical output of Ras activation is the Erk/Mapk pathway ([@bib45]). To determine whether a reduction in Erk activity is sufficient to extend lifespan, we used RNAi to knock down expression of the *Drosophila* ortholog of *Erk*, *rolled* (*rl*^*\[RNAi\]*^). Adult-onset, ubiquitous RNAi knockdown of *rl* significantly increased lifespan ([Figure 2](#fig2){ref-type="fig"}C, median survival +6%, p = 1.46 × 10^−7^). Taken together, these data demonstrate that direct inhibition of Ras-Erk signaling can extend lifespan.

The *Drosophila* gut and fat body, the latter functionally equivalent to mammalian liver and adipose, have an evolutionarily conserved function in aging ([@bib20]). We therefore examined whether confining Ras-Erk inhibition to these organs is sufficient to extend lifespan. Using the inducible, gut- and fat body-specific *S*~*1*~*106* driver ([@bib38]), we expressed *ras*^*\[DN\]*^, *ras85D*^*\[RNAi\]*^, or *rl*^*\[RNAi\]*^ specifically within these tissues. In each case, induction of expression with RU486 resulted in significant extension of lifespan ([Figures 2](#fig2){ref-type="fig"}D--2F, p = 3 × 10^−3^, p = 4 × 10^−4^ and p = 1 × 10^−5^, median lifespan +7%, +1%, and +5%, respectively). Knockdown of *ras85D* produced smaller effects on lifespan than expression of *ras*^*\[DN\]*^, possibly reflecting redundancy between Ras85D and the two other *Drosophila* Ras homologs, Ras64B and Roughened, which are also expressed in the adult fat body ([@bib10]). Nevertheless, our data clearly show that inhibition of Ras-Erk signaling in just these two tissues is sufficient to extend lifespan.

The ETS Transcription Factor, Aop, Mediates Ras-Dependent Lifespan Effects {#sec2.3}
--------------------------------------------------------------------------

Key outputs of the Ras-Erk-signaling pathway during *Drosophila* development are two ETS TFs: Pointed (Pnt), a transcriptional activator stimulated by the Ras-Erk pathway, and Anterior open (Aop), a transcriptional repressor inhibited by the pathway. These two TFs regulate the same genes by binding to the same regulatory elements but with opposing outcomes ([@bib9; @bib22; @bib34]). Inhibition of Ras activity promotes the nuclear localization of Aop in *Drosophila* larvae, and we found that, similarly, adult-onset expression of *ras*^*\[DN\]*^ using the *S*~*1*~*106* driver resulted in a significant increase in nuclear Aop in the adult fat body ([Figure 3](#fig3){ref-type="fig"}A, p = 5 × 10^−3^).

To further assess the transcriptional activity of Aop upon Ras inhibition, we first had to identify Aop targets in the adult. An activated form of Aop (Aop^\[ACT\]^), mutated for eight Mapk phosphorylation sites and hence resistant to repression by Erk, shows high transcriptional activity in vivo ([@bib9; @bib34; @bib39]). Microarray analysis of gene expression in adult fat bodies identified two neighboring genes, *la costa* (*lcs*) and *CG1678*, as strongly repressed after induction of *aop*^*\[ACT\]*^ ([@bib2]). Quantitative RT-PCR on RNA isolated from abdominal fat bodies confirmed this repression ([Figure 3](#fig3){ref-type="fig"}B, p \< 10^−4^). Consistent with *lcs* and *CG1678* being targets of Aop in the adult fat body, expression of an active form of *pnt* (*pnt*^*\[P1\]*^) increased their transcript levels ([Figure 3](#fig3){ref-type="fig"}B, p = 0.02) while expression of *ras*^*\[DN\]*^ decreased their expression upon RU486 induction ([Figure 3](#fig3){ref-type="fig"}B, effect of RU486, p = 0.02). Together with the increase in nuclear localization of Aop, this strongly indicates that Ras inhibition activates Aop in the adult fat body.

We have recently shown that expression of *aop*^*\[ACT\]*^ in the gut and fat body of adult *Drosophila* can extend lifespan ([@bib2]). We therefore examined whether Ras and Aop act in the same pathway to influence adult lifespan. We previously showed that targeted knockdown of *aop* expression specifically in the adult gut and fat body using RNAi has no significant effect on lifespan ([@bib2]). RNAi-mediated knockdown of *aop* expression was, however, sufficient to completely block the lifespan extension associated with gut and fat body expression of *ras*^*\[DN\]*^ ([Figure 3](#fig3){ref-type="fig"}C; RU486 had a significant effect on the lifespan of *S*~*1*~*106 \> ras*^*\[DN\]*^ flies, median lifespan +11%, p = 2 × 10^−6^, but not in *S*~*1*~*106 \> ras*^*\[DN\]*^*aop*^*\[RNAi\]*^ flies, p = 0.95). CPH analysis confirmed that there was a significant difference in the response to RU486 in the two lines (RU486 by genotype interaction, p = 3.2 × 10^−3^, [Table S3](#mmc4){ref-type="supplementary-material"}A). Hence, Aop is required for the beneficial effects of Ras inhibition on lifespan.

We next tested whether inhibition of Ras can increase lifespan in addition to activation of Aop in the adult gut and fat body. Inducing *ras*^*\[DN\]*^ expression in flies already expressing *aop*^*\[ACT\]*^ did not result in any further increase in lifespan ([Figure 3](#fig3){ref-type="fig"}D). Indeed, CPH detected a significant effect of RU486 (p \< 10^−4^) but found no significant difference in the response to RU486 between *S*~*1*~*106 \> aop*^*\[ACT\]*^ and *S*~*1*~*106 \> aop*^*\[ACT\]*^*ras*^*\[DN\]*^ flies (RU486 by genotype interaction p = 0.35, [Table S3](#mmc4){ref-type="supplementary-material"}B). Thus, inhibition of Ras does not further increase lifespan once Aop is already activated. Together with the data presented above, this suggests that Aop is both necessary and sufficient to mediate the effects of Ras inhibition on lifespan.

AOP Is Required for *chico*-Dependent Lifespan Extension {#sec2.4}
--------------------------------------------------------

Our observation that impairing the ability of Chico to signal through to Ras was sufficient to extend lifespan prompted us to test whether Aop transcriptional activity also contributes to IIS-dependent lifespan extension. Ubiquitous targeted knockdown of *aop* expression by RNAi in otherwise wild-type flies significantly impaired their survival ([Figure 4](#fig4){ref-type="fig"}A, p = 2.36 × 10^−16^). Mutation of *chico* significantly increased lifespan in non-induced *daGS \> aop*^*\[RNAi\]*^ (median lifespan +5%, p = 1.20 × 10^−5^), but not in RU486-induced flies (p = 0.95). CPH confirmed that the presence of the *chico* mutation had a significantly different impact on the lifespan of *daGS \> aop*^*\[RNAi\]*^ flies in the presence or absence of RU486 ([Table S4](#mmc5){ref-type="supplementary-material"}A, p = 3.2 × 10^−3^).

The activity of Aop counteracts that of the Pnt transcriptional activator, and hence, similarly to a reduction in Aop activity, increased Pnt activity should also block any effects of *chico* on survival. Ubiquitous expression of the constitutively active form of Pnt, *pnt*^*\[P1\]*^ in otherwise wild-type flies significantly impaired their survival ([Figure 4](#fig4){ref-type="fig"}B, p = 1.66 × 10^−50^). Their lifespan could not be extended by *chico* mutation (p = 0.64, [Figure 4](#fig4){ref-type="fig"}B) but remained responsive to dietary yeast ([Figure S2](#figs2){ref-type="fig"}B). At the same time, *chico* mutation significantly increased lifespan in non-induced flies (median lifespan +12%, p = 2.33 × 10^−9^). CPH analysis of the survival data confirmed that the presence of the *chico* mutation had a significantly different impact on the lifespan of *daGS \> pnt*^*\[P1\]*^ flies in the presence or absence of RU486 ([Table S4](#mmc5){ref-type="supplementary-material"}B, p = 1.4 × 10^−6^). Thus, counteracting the activity of Aop by increasing that of Pnt specifically blocked any beneficial effects of *chico* mutation on survival.

We also tested whether induction of *aop*^*\[ACT\]*^ in the gut and fat body could increase lifespan in addition to *chico* mutation. Each intervention alone produced a significant increase in median lifespan of 7% ([Figure 4](#fig4){ref-type="fig"}C, *aop*^*\[ACT\]*^ expression, p = 3.20 × 10^−13^; *chico* mutation, p = 8.84 × 10^−7^). However, the effects of each intervention on lifespan extension were less than additive ([Figure 4](#fig4){ref-type="fig"}C and [Table S4](#mmc5){ref-type="supplementary-material"}C). We also confirmed that *dfoxo* is required for the lifespan extension of *chico* heterozygous mutation ([Figure 4](#fig4){ref-type="fig"}D; see [Table S4](#mmc5){ref-type="supplementary-material"}D for details). Taken together, these data show that, similarly to Foxo, Aop functions downstream of *chico* and is essential for *chico-*dependent lifespan extension.

Pharmacological Inhibition of Ras-Erk-ETS Signaling Extends Lifespan {#sec2.5}
--------------------------------------------------------------------

The prolific role of Ras-Erk-ETS signaling in cancer has fueled an intense search for small-molecule inhibitors targeting this pathway. Trametinib, an FDA-approved drug for the treatment of melanoma, is one such potent and highly specific inhibitor of the Mek kinase, preventing activation of Erk by Ras ([@bib52]).

We first confirmed that trametinib inhibits Erk activation in *Drosophila* S2 cells. Pre-treatment with trametinib over a wide range of concentrations completely blocked both basal and insulin-stimulated Erk activation ([Figure 5](#fig5){ref-type="fig"}A). Furthermore, cells treated with the highest dose of 10 μM trametinib did not show any inhibition of insulin-stimulated Akt or S6K phosphorylation ([Figure 5](#fig5){ref-type="fig"}B). Thus, trametinib is a potent and specific inhibitor of Ras-Erk signaling in flies.

To validate the Ras-Erk-ETS pathway as a drug target for extension of animal lifespan, we tested the effects of trametinib on *Drosophila* survival. Since loss-of-function mutants for *Drosophila ras* are female sterile ([@bib41]), we first monitored the effects of the drug on female egg laying in order to determine the biologically relevant doses ([Figure 5](#fig5){ref-type="fig"}C). The drug was administered to adult flies orally by supplementation in the food medium, and we selected the doses that produced small to essentially complete inhibition of egg production (1.56 μM to 156 μM) for lifespan assays. Based on quantifications of daily *Drosophila* food intake ([@bib12]), we estimate that flies housed on food containing 1.56 μM trametinib ingest ∼0.4 mg/kg body weight of the drug per day, which is comparable to the oral dose used in mammalian studies of 1 mg/kg body weight ([@bib52]) and the treatment dose of 2 mg per day for human cancer patients ([@bib24]).

1.56 μM and 15.6 μM trametinib significantly increased fly lifespan ([Figure 5](#fig5){ref-type="fig"}D: 1.56 μM, median lifespan +8%, p = 2.65 × 10^−4^; 15.6 μM, median lifespan +12%, p = 1.92 × 10^−10^). CPH analysis revealed that, in this dose range, the risk of death per day was reduced by 4.7% per μM of trametinib (95% CI: 2.9%--6.3%, [Table S5](#mmc6){ref-type="supplementary-material"}A). Mortality analysis showed that treatment with 15.6 μM trametinib reduced demographic frailty (baseline mortality) with no significant difference in the rate of change of mortality with age ([Figure S3](#figs3){ref-type="fig"}). Such a change in baseline mortality would be preferable for a pharmacological intervention for aging, since it would delay the onset of mortality without prolonging the duration of age-related decline. Higher trametinib concentrations (156 μM) resulted in early life mortality but improved survival later in life, resulting in significant increases in maximum, but not median, lifespan. Importantly, no significant effects of trametinib were observed on feeding behavior at doses conducive to lifespan extension ([Figure S4](#figs4){ref-type="fig"}).

For any pharmacological intervention into aging, it is important it be beneficial even when started late in life. We therefore administered the drug to female flies from 30 days post-eclosion, when egg laying has almost ceased ([Figure S5](#figs5){ref-type="fig"}). This late administration also resulted in a significant extension of lifespan ([Figure 5](#fig5){ref-type="fig"}E and [Table S5](#mmc6){ref-type="supplementary-material"}B, median lifespan + 4%, p = 5.02 × 10^−5^). Continuous exposure to the drug resulted in bigger effects on lifespan than when drug administration was restricted to later life, possibly reflecting cumulative effects of earlier drug exposure.

To confirm that trametinib extends lifespan by inhibition of Ras-Erk-ETS signaling, we examined the effects of trametinib on the survival of flies expressing constitutively active Ras or constitutively active Pnt. In the presence of RU486, trametinib treatment at 15.6 μM doubled the lifespan of *daGS \> ras*^*\[CA\]*^ ([Figure 5](#fig5){ref-type="fig"}F, p = 1.24 × 10^−39^), while the survival of *daGS \> pnt*^*\[P1\]*^ was unaffected by drug treatment ([Figure 5](#fig5){ref-type="fig"}F, p = 0.59). CPH analysis confirmed that trametinib had a significantly different impact on the lifespan of *daGS \> ras*^*\[CA\]*^ flies compared to *daGS \> pnt*^*\[P1\]*^ flies in the presence RU486 ([Table S5](#mmc6){ref-type="supplementary-material"}C, p \< 2 × 10^−16^). In the absence of transgene expression, 15.6 μM trametinib treatment significantly increased the lifespan of both genotypes ([Figure S6](#figs6){ref-type="fig"}). Hence, trametinib acts specifically between Ras and Pnt to extend fly lifespan. In summary, our data confirm that the Ras-Erk-ETS pathway is a valid drug target for extension of animal lifespan.

Trametinib Does Not Act on Lifespan via Modulation of Stem Cell Proliferation {#sec2.6}
-----------------------------------------------------------------------------

Inhibition of Ras-Erk signaling can have substantial effects on cell proliferation. Adult *Drosophila* somatic tissues are predominantly post-mitotic, although a population of adult stem cells resides in the midgut, and their proliferative capacity, in part regulated by Ras-Erk signaling, is important for lifespan ([@bib4; @bib5]). To test whether trametinib affects age-dependent intestinal stem cell (ISC) proliferation rates, we determined the frequency of phospho-histone H3-positive (pH3+) cells, a marker of cell-cycle progression and a direct measurement of ISC proliferation ([@bib5]). The number of PH3+ cells increased 5-fold from 15 to 65 days in control flies, and continuous exposure to 1.56 μM or 15.6 μM trametinib did not prevent this age-dependent increase in ISC proliferation ([Figure 5](#fig5){ref-type="fig"}G). Hence, trametinib does not significantly affect stem cell proliferation at doses that extend lifespan.

To further confirm that gut function was unaffected by trametinib, we examined gut intestinal barrier function, which is a good indicator of overall intestinal integrity and is important for survival ([@bib40]). Flies were fed a non-absorbable blue food dye, and "smurf" flies, in which the gut is unable to prevent this dye from leaking into the hemolymph, scored ([@bib40]). The proportion of smurfs in the control population increased by 8-fold from 15 to 65 days ([Figure 5](#fig5){ref-type="fig"}H). Again, trametinib did not alter this age-dependent loss of intestinal epithelial integrity ([Figure 5](#fig5){ref-type="fig"}H). Consistent with these observations, we found that adult-onset expression of Aop^\[ACT\]^ specifically within the ISCs is not sufficient to extend lifespan ([Figure 5](#fig5){ref-type="fig"}I and [Table S5](#mmc6){ref-type="supplementary-material"}D, p = 0.45). Hence, the effects of pharmacological or genetic manipulation of Ras-Erk-ETS signaling cannot be explained by the modulation of ISC proliferation and maintenance of gut function.

Discussion {#sec3}
==========

Ras-Erk-ETS Signaling as an Effector of the IIS Longevity Response {#sec3.1}
------------------------------------------------------------------

The key role of IIS in determining animal lifespan has been well appreciated for more than two decades and shows strong evolutionary conservation ([@bib20; @bib25]). Alleles of genes encoding components of this pathway have also been linked to longevity in humans ([@bib7; @bib26; @bib46]). Multiple studies have demonstrated the importance of the PI3K-Akt-Foxo branch of IIS, while in this study we identify an equally important role for Ras-Erk-ETS signaling in IIS-dependent lifespan extension.

We have shown that, downstream of *chico*, preventing the activation of either Ras or PI3K is sufficient to extend lifespan. Ras can interact directly with the catalytic subunit of PI3K, which is required for maximal PI3K activation during growth ([@bib36]). Thus, inhibition of Ras could increase lifespan via inactivation of PI3K. However, several lines of evidence indicate that the Erk-ETS pathway must also, if not solely, be involved. In this study and elsewhere, we demonstrated that direct inhibition of the Ras-dependent kinase, Erk, or activation of the Aop transcription factor, a negative effector of the Ras-Erk pathway, is sufficient to extend lifespan. Importantly, we show that Ras-Erk-ETS signaling is genetically linked to *chico* because activation of Aop is required for lifespan extension due to *chico* loss of function. Furthermore, altering the ability of Chico to activate Ras or PI3K does not result in equivalent phenotypes: we and others ([@bib35]) showed that mutation of the Grb2/Drk docking site in Chico is dispensable for multiple developmental phenotypes associated with *chico* mutation, while disruption of the Chico-PI3K interaction is not. Overall, our observations strongly suggest that lifespan extension downstream of *chico* mutation involves inhibition of the Ras-Erk-ETS-signaling pathway.

The simplest model to integrate the role of Ras-Erk-ETS signaling with the PI3K-Akt-Foxo branch in extension of lifespan by reduced IIS is presented in [Figure 6](#fig6){ref-type="fig"}. We propose that, downstream of Chico, the IIS pathway bifurcates into branches delineated by Erk and Akt, with inhibition of either sufficient to extend lifespan, as is activation of either responsive TF, Aop or Foxo. The two branches are not redundant, because mutation of *chico* or the loss of its ability to activate either branch results in the same magnitude of lifespan extension. Furthermore, Aop and Foxo are each individually required downstream of *chico* mutation for lifespan extension. At the same time, the effects of the two branches are not additive, as simultaneous activation of Aop and Foxo does not extend lifespan more than activation of either TF alone ([@bib2]). Taken together, these data suggest that the two pathways re-join for transcriptional regulation, where Aop and Foxo co-operatively regulate genes required for lifespan extension. Our model is corroborated by our previous finding that, in the adult gut and fat body, some 60% of genomic locations bound by Foxo overlap with regions of activated-Aop binding ([@bib2]). We propose that functional interactions of Aop and Foxo at these sites may be such that each factor is both necessary and sufficient to achieve the beneficial changes in target gene expression upon reduced IIS.

It remains to be determined how promoter-based Foxo and Aop interactions produce such physiologically relevant, transcriptional changes. It is, however, curious that activation of either TF alone promotes longevity when one is known as a transcriptional activator (Foxo) and the other as a transcriptional repressor (Aop). We have consistently observed a subset of Foxo-bound genes, albeit a minority, that are transcriptionally repressed when Foxo is activated ([@bib1; @bib2]). Furthermore, the Foxo target gene *myc* is downregulated in larval muscle when Foxo is active under low insulin conditions, while deletion of *foxo* or its binding site within the *myc* promoter results in de-repression of myc expression in adipose of fed larvae ([@bib49]). Thus, on some promoters under certain conditions, *Drosophila* Foxo appears to act as a transcriptional repressor. Mammalian Foxo3a may also directly repress some genes ([@bib51; @bib54]). It will therefore be important to test whether the lifespan-relevant interactions between Foxo and Aop occur on promoters where Foxo acts as a repressor with Foxo possibly acting as a cofactor for Aop or vice versa.

In mediating the effects of IIS on lifespan, the Ras-Erk-ETS- and PI3K-Akt-Foxo-signaling pathways both appear to inhibit Aop/Foxo. To understand why signaling might be so wired, it is important to consider that the two pathways are also regulated by other stimuli, such as other growth factors, stress signals, and nutritional cues. The re-joining of the two branches at the transcriptional level would therefore allow for their outputs to be integrated, producing a concerted transcriptional response, a feature that is also seen in other contexts. For example, stability of the Myc transcription factor is differentially regulated in response to Erk and PI3K signals, allowing it to integrate signals from the two kinases ([@bib28]). Transcriptional integration in response to RTK signaling also confers specificity during cell differentiation, with combinatorial effects of multiple transcriptional modulators inducing tissue-specific responses to inductive Ras signals ([@bib22]). Similar integrated responses of lifespan could be orchestrated by transcriptional coordination of Aop and Foxo.

A Role for Ras-Erk-ETS Signaling in Mammalian Aging {#sec3.2}
---------------------------------------------------

We find that direct inhibition of Ras in *Drosophila* can extend lifespan, suggesting that the role of Ras in aging is evolutionarily conserved. In budding yeast, deletion of *RAS1* extends replicative lifespan ([@bib47]), and deletion of *RAS2* increases chronological lifespan by altering signaling through cyclic-AMP/protein kinase A (cAMP/PKA) ([@bib17]), downregulation of which is sufficient to extend both replicative and chronological lifespan ([@bib16; @bib18; @bib29]). This role of cAMP/PKA in aging may be conserved in mammals, as disruption of adenylyl cyclase 5′ and PKA function extend murine lifespan ([@bib15; @bib53]). However, cAMP/PKA are not generally considered mediators of Ras function in metazoa. Instead, our data suggest that signaling through Erk and the ETS TFs mediates the longevity response to Ras. Interestingly, fibroblasts isolated from long-lived mutant strains of mice and long-lived species of mammals and birds show altered dynamics of Erk phosphorylation in response to stress ([@bib14; @bib48]), further suggesting a link between Erk activity and longevity. Importantly, the ETS TFs are conserved mediators of Ras-Erk signaling in mammals ([@bib43]). Investigation of the effects of Ras inhibition on mammalian lifespan and the role of the mammalian Aop ortholog Etv6 are now warranted.

Ras-Erk-ETS Inhibitors as Potential Anti-Aging Therapeutics {#sec3.3}
-----------------------------------------------------------

A role for Ras-Erk-ETS signaling in lifespan offers multiple potential targets for small-molecule inhibitors that could function as anti-aging interventions. Importantly, due to the key role of this pathway in cancer, multiple such inhibitors exist or are in development ([@bib33]).

We have shown that trametinib, a highly specific allosteric inhibitor of the Mek kinase ([@bib52]), prolongs *Drosophila* lifespan, thus validating the Ras-Erk-ETS pathway as a pharmacological target for anti-aging therapeutics. Trametinib joins a very exclusive list of FDA-approved drugs that promote longevity in animals ([@bib11]), the most convincing other example being rapamycin.

Rapamycin not only increases lifespan in multiple organisms, including mammals, but also improves several indices of function during aging ([@bib13; @bib27]). While rapamycin can protect against tumor growth ([@bib3]), the effects on longevity appear to be independent of cancer prevention, as rapamcyin-treated animals still develop tumors ([@bib23]) and rapamycin can increase lifespan in tumor-free species ([@bib6]). Furthermore, increased activity of certain tumor suppressors such as lnk4a/Arf and PTEN as well as the *RasGrf1* deficiency all increase lifespan independently of anti-tumor activity ([@bib8; @bib31; @bib37]). Our findings that trametinib can increase lifespan in *Drosophila*, which are mainly post-mitotic in adulthood, and that doses of trametinib that increase lifespan do not alter proliferation rates of ISCs in *Drosophila* suggest that the anti-aging effects of trametinib are separable from its anti-cancer activity.

Finally, due to the high degree of evolutionary conservation in the Ras-Erk-ETS pathway, our study suggests the intriguing possibility that pharmacological inhibition of Ras-Erk-ETS may also increase lifespan in mammals.

Experimental Procedures {#sec4}
=======================

Fly Stocks and Husbandry {#sec4.1}
------------------------

Stocks were maintained and experiments conducted at 25°C on a 12 hr:12 hr light:dark cycle at 60% humidity, on food containing 10% (w/v) brewer's yeast, 5% (w/v) sucrose, and 1.5% (w/v) agar unless otherwise noted. RU486 (Sigma) dissolved in ethanol was added to a final concentration of 200 μM. Trametinib (LC Laboratories) was added from a 62.4 mM stock solution in DMSO maintaining a final DMSO concentration of 0.25% (v/v). For control treatments, equivalent volumes of the vehicle alone were added. Stocks were backcrossed for at least six generations into the wild-type outbred *wDahomey* population, with the exception of *UAS-ras85D*^*\[RNAi\]*^ and *UAS-rl*^*\[RNAi\]*^, which were used as hybrids. *Drosophila* stocks, cloning strategies, and phenotyping are described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. For lifespans, flies were sorted into experimental vials at a density of 10 or 15 flies per vial. Flies were transferred to fresh vials three times a week, and deaths/censors were scored during transferral.

Bimolecular Fluorescence Complementation Assays {#sec4.2}
-----------------------------------------------

Constructs encoding the wild-type Chico protein or Chico Grb2/Drk-binding site mutant and *Drosophila* Drk were transfected into S2 cells. After 3 days, cells were serum starved for 2 hr and then stimulated with 1 μM human insulin (Sigma) for 24 hr before imaging.

Immunofluorescence {#sec4.3}
------------------

Aop immunofluorescence was performed on dissected adult abdominal fat bodies using a monoclonal mouse anti-AOP antibody ([@bib39]) at 1:100 dilution. Phospho-histone H3 immunofluorescence was performed on dissected adult midguts using a polyclonal rabbit phospho-histone H3 (Ser10) antibody (Cell Signaling).

Western Blots {#sec4.4}
-------------

S2 cells were serum starved for 2 hr, treated with trametinib dissolved in DMSO or DMSO alone for 30 min, and then stimulated with 1 μM human insulin (Sigma) for 15 min. Western blots were probed for phospho-Erk(Thr202/Tyr204) (\#4370), phospho-Akt(Ser473) (\#4060), phospho-S6K(Thr398) (\#9209), total-Erk (\#4695), total-Akt (\#9272) (Cell Signaling Technologies), total-S6K, and tubulin.

qRT-PCR Analysis {#sec4.5}
----------------

Total RNA was isolated from either five whole adult flies or five dissected abdominal fat bodies using standard TRIZOL (Invitrogen) protocols and converted to cDNA using oligod(T) primer and Superscript II reverse transcriptase (Invitrogen). Quantitative RT-PCR was performed using Power SYBR Green PCR Master Mix (ABI), and relative quantities of transcripts were determined using the relative standard curve method normalized to *actin5C*. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for primer sequences.

Statistical Analysis {#sec4.6}
--------------------

Statistical analysis was performed in Excel (Microsoft), Jmp version 9 (SAS Insitute), or R, except for mortality analysis in which survival data were fitted to the Gompertz model using Survomatic online. Statistical tests used are indicated in the figure captions. See the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for further details.
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![Ras Inhibition Functions Downstream of IIS to Extend Lifespan\
(A) Chico protein sequence with amino acid substitutions used to generate the Chico-Grb2/Drk- and Chico-PI3K-binding site mutants.\
(B) BiFC in S2 cells co-expressing the indicated Chico constructs with the *Drosophila* Drk protein. Proportion of YFP-positive cells ± SE; n numbers are indicated above each bar; ^∗∗^p \< 0.005 Chi-square test to no insulin control. Scale bar, 10 μm.\
(C) Egg-to-adult development time of the indicated genotypes. See also [Figure S1](#figs1){ref-type="fig"}.\
(D) Fresh weight of adult females of the indicated genotypes. Mean body mass (n = 10 for each genotype) ± SEM, Anova, p \< 0.0001, ^∗∗^p \< 0.05 t test (compared to WT).\
(E) Survival of wild-type and *chico/+* heterozygous females carrying the indicated *chico* genomic rescue constructs. *chico/+* flies were long-lived compared to *WT* (p = 0.0006), which was rescued by the *chico* rescue construct (p = 0.58). Both the Grb2/Drk mutant and the PI3K mutant failed to rescue the longevity of *chico/+* flies (compared to WT construct, p = 8.36 × 10^−10^ and p = 1.32 × 10^−9^, respectively). See [Table S1](#mmc2){ref-type="supplementary-material"}A.\
(F) Expression of constitutively active Ras blocks the beneficial effects of *chico* mutation on survival. *daGS/chico \> ras*^*\[CA\]*^ flies show increased lifespan compared to *daGS \> ras*^*\[CA\]*^ in the absence of RU486 (p = 3.07 × 10^−18^), but not in the presence of RU486 (p = 0.18). See [Table S1](#mmc2){ref-type="supplementary-material"}B.](gr1){#fig1}

![Direct Inhibition of Ras-Erk Signaling Extends Lifespan\
(A) Ubiquitous adult-onset expression of *ras*^*\[DN\]*^ increases lifespan (p = 1.26 × 10^−7^). See [Table S2](#mmc3){ref-type="supplementary-material"}A.\
(B) Ubiquitous adult onset of *ras85D* knockdown by RNAi increases lifespan (p = 2 × 10^−3^). See [Table S2](#mmc3){ref-type="supplementary-material"}B.\
(C) Ubiquitous adult-onset knockdown of *rl* expression by RNAi increases lifespan (p = 1.46 × 10^−7^). See [Table S2](#mmc3){ref-type="supplementary-material"}C.\
(D) Adult gut/fat body expression of *ras*^*\[DN\]*^ extends lifespan (p = 3 × 10^−3^). See [Table S2](#mmc3){ref-type="supplementary-material"}D.\
(E) Adult gut/fat body knockdown of *ras85D* expression by RNAi extends lifespan (p = 4 × 10^−4^). See [Table S2](#mmc3){ref-type="supplementary-material"}E.\
(F) Adult gut/fat body knockdown of *rl* expression by RNAi extends lifespan (p = 10^−5^). See [Table S2](#mmc3){ref-type="supplementary-material"}F.](gr2){#fig2}

![Aop Functions Downstream of Ras in the Adult Fly to Control Lifespan\
(A) Nuclear localization of Aop protein (red) increases in intensity in dissected adult abdominal fat bodies of *S*~*1*~*106 \> ras*^*\[DN\]*^ females fed RU486. (n = 5, p = 5 × 10^−3^, t test). Nuclei are stained with DAPI (white). Scale bar, 25 μm. Intensity quantifications are shown as box plots.\
(B) Box plots of log-transformed levels of lacosta (lcs) and CG1678 mRNAs relative to actin in females of the indicated genotypes. *S*~*1*~*106 \> aop*^*\[ACT\]*^: mixed effects linear model (MELM) (n = 3--4): significant effect of RU486 (p \< 10^−4^), transcript (p = 2 × 10^−3^) and their interaction (p = 4 × 10^−3^), with significant differences between -- and + RU486 for each transcript (p \< 0.05, post hoc t test); *S*~*1*~*106*\>*pnt*^*\[P1\]*^: significant effect of RU486 only (p = 0.02, n = 4, MELM); *S*~*1*~*106*\>*ras*^*\[DN\]*^ significant effect of RU486 only (p = 0.02, n = 4, MELM).\
(C) *S*~*1*~*106 \> ras*^*\[DN\]*^ show increased lifespan in the presence of RU486 (p = 2 × 10^−6^), but *S*~*1*~*106 \> ras*^*\[DN\]*^*aop*^*\[RNAi\]*^ females do not (p = 0.95). See [Table S3](#mmc4){ref-type="supplementary-material"}A.\
(D) *S*~*1*~*106 \> aop*^*\[ACT\]*^ females show increased lifespan in the presence of RU486 (p = 2 × 10^−5^). *S*~*1*~*106 \> aop*^*\[ACT\]*^*ras*^*\[DN\]*^ females also show increased lifespan in the presence of RU486 (p = 4x10^−6^) but are no longer lived than *S*~*1*~*106 \> aop*^*\[ACT\]*^. See [Table S3](#mmc4){ref-type="supplementary-material"}B.](gr3){#fig3}

![The Ras-Regulated Transcription Factor, Aop, Is Required Downstream of *chico* to Increase Survival\
(A) *chico* extends lifespan in *daGS \> aop*^*\[RNAi\]*^ females in the absence of RU486 (p = 1.2 × 10^−5^), but not in the presence of RU486 (p = 0.95). See [Table S4](#mmc5){ref-type="supplementary-material"}A.\
(B) *chico* extends lifespan in *daGS \> pnt*^*\[P1\]*^ females in the absence of RU486 (p = 2.34 × 10^−9^), but not in the presence of RU486 (p = 0.64). See [Table S4](#mmc5){ref-type="supplementary-material"}B.\
(C) The effects of *chico/*~*+*~ mutation and *S*~*1*~*106 \> aop*^*\[ACT\]*^ are not additive for lifespan (*S*~*1*~*106 \> aop*^*\[ACT\]*^ versus *S*~*1*~*106/chico \> aop*^*\[ACT\]*^ in the RU486− condition, p = 8.84 × 10^−7^; *S*~*1*~*106 \> aop*^*\[ACT\]*^ RU486− versus RU486+ conditions, p = 3.20 × 10^−13^; *S*~*1*~*106/chico \> aop*^*\[ACT\]*^ RU486− versus RU486+, p = 0.29). See [Table S4](#mmc5){ref-type="supplementary-material"}C.\
(D) *dfoxo* is required for *chico/+* lifespan extension. *chico/+* females show increased lifespan (p = 3.71 × 10^−6^), but not in the absence of *dfoxo* (p = 0.63). See [Table S4](#mmc5){ref-type="supplementary-material"}D.](gr4){#fig4}

![Pharmacological Inhibition of Ras-Erk Signaling Using Trametinib Extends Lifespan\
(A) *Drosophila* S2 cells treated with trametinib (Tram) at the indicated concentrations show inhibition of insulin-stimulated (Ins) Erk phosphorylation.\
(B) S2 cells treated with a high concentration of trametinib (10 μM) show no inhibition of insulin-dependent phosphorylation of Akt or S6K.\
(C) Effects of trametinib dose on female egg laying. Means ± SEM, ^∗∗^p \< 0.05 t test (compared to 0 μM condition).\
(D) Trametinib extends lifespan in *wDah* females.(1.56 μM, p = 2.65 × 10^−4^; 15.6 μM, p = 1.92 × 10^−10^). See [Table S5](#mmc6){ref-type="supplementary-material"}A.\
(E) Later-life (day 30) post-reproductive (see also [Figure S5](#figs5){ref-type="fig"}) exposure to 15.6 μM trametinib extends lifespan (p = 5.02 × 10^−5^). See [Table S5](#mmc6){ref-type="supplementary-material"}B.\
(F) Trametinib increases survival of *daGS \> ras*^*\[CA\]*^ (p = 1.24 × 10^−39^), but not *daGS \> pnt*^*\[P1\]*^ flies (p = 0.59) in the presence of RU486. See [Table S5](#mmc6){ref-type="supplementary-material"}C.\
(G) Age-related changes in gut ISC proliferation in animals exposed to trametinib for 15 or 65 days. Mean number of PH3+ cells per gut ± SEM. Number of guts analyzed are indicated above each bar. GLM with Poisson distribution and overdispersion parameter: significant effect of age (p \< 0.001), but not trametinib concentration (p = 0.84) or their interaction (p = 0.79).\
(H) Age-related changes in intestinal integrity in animals exposed to trametinib for 15 or 65 days. Proportion of smurfs present in the population ± SE. Total numbers of flies examined for each condition are indicated above each bar. GLM with binomial distribution and overdispersion parameter: significant effect of age (p \< 0.001), but not trametinib concentration (p = 0.84) or their interaction (p = 0.79).\
(I) No significant differences in survival of *GS5961 \> aop*^*\[ACT\]*^ females in the presence or absence of RU486 (p = 0.45). See [Table S5](#mmc6){ref-type="supplementary-material"}D.](gr5){#fig5}

![Model of Aop-Foxo Function Downstream of IIS\
We propose that, downstream of the insulin receptor substrate, Chico, signaling via the IIS pathway bifurcates into two branches: Ras-Erk and PI3K-Akt. At the transcriptional level, these two branches subsequently re-join, acting on the Aop and Foxo TFs in a non-additive manner. The two TFs then co-operatively regulate the expression of a subset of target genes required for lifespan extension.](gr6){#fig6}

![Expression Levels and Developmental Phenotypes of *chico* Genomic Rescue Constructs, Related to [Figure 1](#fig1){ref-type="fig"}\
(A) Log-transformed levels of *chico* mRNA relative to *actin* in females of the indicated genotypes. *chico* expression was significantly reduced in *chico* mutants (p \< 0.05, t test compared to WT controls), but not in the presence of any of the genomic rescue constructs. Means ± SEM.\
(B--D) The PI3K-binding site, but not the Grb2/Drk-binding site, of Chico is essential for female sterility (B) and increased metabolic stores (C and D). Means ± SEM, ^∗∗^p \< 0.05, t test (compared to WT controls).](figs1){#figs1}

![Effects of Yeast Concentration on the Survival of Flies Expressing Constitutively Active Ras or Constitutively Active Pointed, Related to [Figures 1](#fig1){ref-type="fig"} and [4](#fig4){ref-type="fig"}\
(A) Survival of *daGS \> ras*^*\[CA\]*^ flies in the presence of RU486 under different dietary yeast concentrations. Log-rank detected a significant increase in survival between 0.5x and 1.0x yeast concentrations (increase in median lifespan of 13%, p = 6.28x10^−8^) and between 1.0x and 2.0x yeast concentrations (increase in median lifespan of 11%, p = 7.41x10^−4^). 0.5x yeast: n = 97 deaths/0 censors, median lifespan = 16 days; 1.0x: n = 89/0, median lifespan = 18 days; 2.0x: n = 86/0, median lifespan = 20 days.\
(B) Survival of *daGS \> pnt*^*\[P1\]*^ flies in the presence of RU486 under different dietary yeast concentrations. Log-rank detected a significant increase in survival between 1.0x and 0.5x yeast concentrations (increase in median lifespan of 40%, p = 4.68x10^−14^) and between 2.0x and 1.0x yeast concentrations (increase in median lifespan of 150%, p = 1.62x10^−37^). 0.5x yeast: n = 163 deaths/0 censors, median lifespan = 28 days; 1.0x: n = 159/0, median lifespan = 20 days; 2.0x: n = 152/0, median lifespan = 8 days.](figs2){#figs2}

![Mortality Analysis of Flies Exposed to 15.6 μM Trametinib, Related to [Figure 5](#fig5){ref-type="fig"}\
(A) Combined survival data from three independent trials of *wDah* females exposed to 15.6 μM trametinib. Log-rank detected a significant difference in survival between trametinib-treated flies and untreated controls (increase in median lifespan of 9%, p \< 0.0001). Controls: n = 338 deaths/8 censors, median lifespan = 75 days; trametinib-treated: n = 325/28, median lifespan = 82 days.\
(B) Age-specific mortality analysis of the survival data in (A). Mortality (μx) was calculated as: μx = -ln(1-qx), where qx (the probability of dying in a time interval) was averaged per day over a 5-day interval and is shown at the end of the interval. Intervals with zero deaths were removed. Estimates of the parameters of the Gompertz mortality model: λ (baseline mortality) controls = 7.3x10^−6^, trametinib-treated = 2.3x10^−6^, p = 0.045; γ (change in mortality with age) controls = 0.13, trametinib-treated = 0.13, p = 0.67.](figs3){#figs3}

![Trametinib Does Not Affect Feeding Behavior, Related to [Figure 5](#fig5){ref-type="fig"}\
Feeding events as a proportion of total events observed per vial for *wDah* females on food containing 0 μM, 1.56 μM and 15.6 μM trametinib (15 vials per condition). Data were analyzed using a Generalized Linear Model with binomial distribution and overdispersion parameter. There was no significant effect of trametinib concentration on feeding (p = 0.66).](figs4){#figs4}

![Egg Laying Over Time in *wDah* Females, Related to [Figure 5](#fig5){ref-type="fig"}\
Egg-laying in *wDah* females peaks at around day 10 post-mating and then declines to plateau by day 28. Means ± SEM.](figs5){#figs5}

![Trametinib Extends the Lifespan of *daGS \> ras*^*\[CA\]*^ and *daGS \> pnt*^*\[P1\]*^ Flies in the Absence of Transgene Expression, Related to [Figure 5](#fig5){ref-type="fig"}\
(A and B) In the absence of RU486 and hence transgene expression, trametinib treatment at 15.6 μM increased the survival of *daGS \> ras*^*\[CA\]*^ flies (increase in median lifespan of 9%, p = 2.07x10^−8^) and *daGS \> pnt*^*\[P1\]*^ flies (increase in median lifespan of 9%, p = 2.69x10^−7^). Untreated *daGS \> ras*^*\[CA\]*^: n = 90 deaths/6 censors, median lifespan = 82 days; trametinib-treated *daGS \> ras*^*\[CA\]*^: n = 95/1, median lifespan = 89 days; untreated *daGS/ pnt*^*\[P1\]*^, n = 141/6, median lifespan = 79 days; trametinib-treated daGS*\> pnt*^*\[P1\]*^, n = 132/19, median lifespan = 86 days.](figs6){#figs6}
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